0000899243-24-000266.txt : 20240405 0000899243-24-000266.hdr.sgml : 20240405 20240405205035 ACCESSION NUMBER: 0000899243-24-000266 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240403 FILED AS OF DATE: 20240405 DATE AS OF CHANGE: 20240405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Taub Rebecca CENTRAL INDEX KEY: 0001423898 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33277 FILM NUMBER: 24827901 MAIL ADDRESS: STREET 1: 750 BATTERY STREET, SUITE 330 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MADRIGAL PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001157601 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 BARR HARBOR DRIVE, SUITE 400 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 BUSINESS PHONE: 404-380-9263 MAIL ADDRESS: STREET 1: 200 BARR HARBOR DRIVE, SUITE 400 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 FORMER COMPANY: FORMER CONFORMED NAME: SYNTA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20010815 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2024-04-03 0 0001157601 MADRIGAL PHARMACEUTICALS, INC. MDGL 0001423898 Taub Rebecca C/O MADRIGAL PHARMACEUTICALS, INC. 200 BARR HARBOR DRIVE, SUITE 200 WEST CONSHOHOCKEN PA 19428 1 1 0 0 Pres., R&D, and CMO 1 Common Stock 2024-04-03 4 M 0 27845 9.45 A 486844 D Common Stock 2024-04-03 4 S 0 135 242.00 D 486709 D Common Stock 2024-04-03 4 S 0 2634 243.6849 D 484075 D Common Stock 2024-04-03 4 S 0 4070 244.6815 D 480005 D Common Stock 2024-04-03 4 S 0 18917 245.3356 D 461088 D Common Stock 2024-04-03 4 S 0 2089 246.3249 D 458999 D Common Stock 2024-04-04 4 M 0 18537 9.45 A 477536 D Common Stock 2024-04-04 4 S 0 4200 240.8759 D 473336 D Common Stock 2024-04-04 4 S 0 5619 241.8528 D 467717 D Common Stock 2024-04-04 4 S 0 3085 242.7114 D 464632 D Common Stock 2024-04-04 4 S 0 435 244.0066 D 464197 D Common Stock 2024-04-04 4 S 0 2734 245.0643 D 461463 D Common Stock 2024-04-04 4 S 0 1653 246.0123 D 459810 D Common Stock 2024-04-04 4 S 0 711 247.2268 D 459099 D Common Stock 2024-04-04 4 S 0 100 248.23 D 458999 D Common Stock 2024-04-05 4 M 0 27506 9.45 A 486505 D Common Stock 2024-04-05 4 S 0 1643 240.1076 D 484862 D Common Stock 2024-04-05 4 S 0 700 241.1413 D 484162 D Common Stock 2024-04-05 4 S 0 8817 242.6073 D 475345 D Common Stock 2024-04-05 4 S 0 8989 243.3294 D 466356 D Common Stock 2024-04-05 4 S 0 2079 244.4509 D 464277 D Common Stock 2024-04-05 4 S 0 5278 245.5332 D 458999 D Common Stock 655540 I By SQN LLC Stock Option (Right to Buy) 9.45 2024-04-03 4 M 0 27845 0.00 D 2026-07-22 Common Stock 27845 125283 D Stock Option (Right to Buy) 9.45 2024-04-04 4 M 0 18537 0.00 D 2026-07-22 Common Stock 18537 106746 D Stock Option (Right to Buy) 9.45 2024-04-05 4 M 0 27506 0.00 D 2026-07-22 Common Stock 27506 79240 D These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.11 to $244.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.11 to $245.10, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.11 to $246.10, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.12 to $246.70, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $240.33 to $241.29, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $241.37 to $242.36, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.38 to $243.35, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.40 to $244.39, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.49 to $245.47, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.52 to $246.50, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.78 to $247.68, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $239.57 to $240.52, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $240.67 to $241.64, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.00 to $242.99, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.00 to $243.95, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.03 to $245.02, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.03 to $245.88, inclusive. The Reporting Person and her spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. The shares underlying this stock option are fully vested and exercisable. Exhibit 24 - Power of Attorney /s/ Mardi Dier, as Attorney-in-Fact 2024-04-05 EX-24 2 attachment1.htm EX-24 DOCUMENT
                                        POWER OF ATTORNEY


        The undersigned hereby constitutes and appoints Bill Sibold, Mardi Dier
and Justin Drinkwine, or any of them signing individually, the undersigned's
true and lawful attorney-in-fact (each, an "Attorney-in-Fact") to:

     (1)    complete and execute, for and on behalf of the undersigned, in the
            undersigned's capacity as an officer, director and/or beneficial
            owner of more than ten percent (10%) of any equity securities of
            Madrigal Pharmaceuticals, Inc., a Delaware corporation (the
            "Company"), Forms 3, 4 and 5, and Schedules 13D and 13G, and such
            other forms and documents, including any amendments to any of the
            foregoing, as such Attorney-In-Fact shall in his or her discretion
            determine to be required or advisable pursuant to Section 16(a) and
            Section 13(d) of the Securities Exchange Act of 1934, as amended
            (the "Exchange Act") and the rules and regulations promulgated
            thereunder, or any successor laws and regulations, as a consequence
            of, or in respect of, the undersigned's ownership, acquisition or
            disposition of securities of the Company;

     (2)    do and perform any and all acts for and on behalf of the undersigned
            which may be necessary or desirable to complete and execute any such
            forms and schedules, including any amendments thereto, and timely
            file such forms and schedules, including any amendments thereto,
            with the United States Securities and Exchange Commission
            (the "SEC"), and any securities exchange or similar authority; and

     (3)    take any other action of any type whatsoever in connection with the
            foregoing which, in the opinion of such Attorney-in-Fact, may be of
            benefit to, in the best interest of, or legally required by, the
            undersigned, it being understood that the documents executed by such
            Attorney-in-Fact on behalf of the undersigned pursuant to this Power
            of Attorney shall be in such form and shall contain such information
            as such Attorney-in-Fact may approve in such Attorney-in-Fact's
            discretion.

        The undersigned hereby grants to each such Attorney-in-Fact full power
and authority to do and perform each and every act and thing whatsoever
requisite, necessary or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution and revocation, hereby ratifying and confirming all that each such
Attorney-in-Fact, or each such Attorney-in-Fact's substitute or substitutes,
shall lawfully do or cause to be done by virtue of this power of attorney and
the rights and powers herein granted.

        The undersigned acknowledges that each of the foregoing Attorneys-in-
Fact, in serving in such capacity at the request of the undersigned, are not
assuming, nor is the Company assuming, any of the undersigned's responsibilities
to comply with Section 16(a) and Section 13(d) of the Exchange Act.

        The undersigned agrees that each such Attorney-in-Fact may rely entirely
on information furnished orally or in writing by the undersigned to each such
Attorney-in-Fact. The undersigned also agrees to indemnify and hold harmless the
Company and each such Attorney-in-Fact against any losses, claims, damages or
liabilities (or actions in these respects) that arise out of or are based on any
untrue statement or omission of necessary facts in the information provided by
the undersigned to such Attorney-in-Fact for purposes of executing,
acknowledging, delivering and filing Forms 3, 4 and 5, and Schedules 13D and
13G, including any amendments thereto, and agrees to reimburse the
Company and each such Attorney-in-Fact for any legal or other expenses
reasonably incurred in connection with investigating or defending against any
such loss, claim, damage, liability or action.

        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5, or Schedules 13D and
13G, with respect to the undersigned's holdings of and transactions in
securities issued by the Company, unless earlier revoked by the undersigned
in a signed writing delivered to the foregoing Attorneys-in-Fact.


                               [Signature on next page]


IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of:


4/4/2024
---------------------------------
	(date)


                                                /s/ Rebecca Taub
                                                --------------------------------
                                                Rebecca Taub, M.D.